Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 5Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 49Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma 9Recurrence 7Lymphoma, Non-Hodgkin 7Neoplasms 6Lymphoma, Mantle-Cell 5Lymphoma, B-Cell 4Neoplasms, Plasma Cell 3Neoplasm, Residual 3Lymphoma, T-Cell, Peripheral 3Smoldering Multiple Myeloma 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vitamin D Deficiency 1Peripheral Nervous System Diseases 1Paraproteinemias 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Diseases 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Corneal Diseases 1Cardiotoxicity 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 22fludarabine 20venetoclax 8Whole-Body Irradiation 8Mycophenolic Acid 8Standard of Care 6Mesna 6Melphalan 6Azacitidine 6fludarabine phosphate 5Sirolimus 5thymoglobulin 4Thiotepa 4Tacrolimus 4Surveys and Questionnaires 4Specimen Handling 4Filgrastim 4Cytarabine 4entrectinib 3daratumumab 3cobimetinib 3alectinib 3Vemurafenib 3Rituximab 3Practice Guidelines as Topic 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Busulfan 3Bortezomib 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hematologic Neoplasms × Lenalidomide × Clear all
NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT05828459 2025-03-20

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Onward Therapeutics

Phase 1 Recruiting
150 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡